Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Phase I trial of weekly gemcitabine at 3-h infusion in refractory, heavilypretreated advanced solid tumors
Autore:
Maurel, J; Zorrilla, M; Puertolas, T; Anton, A; Herrero, A; Artal, A; Alonso, V; Martinez-Trufero, J; Puertas, MD;
Indirizzi:
Miguel Servet Univ Hosp, Med Oncol Serv, Zaragoza, Spain Miguel Servet Univ Hosp Zaragoza Spain Med Oncol Serv, Zaragoza, Spain
Titolo Testata:
ANTI-CANCER DRUGS
fascicolo: 9, volume: 12, anno: 2001,
pagine: 713 - 717
SICI:
0959-4973(200110)12:9<713:PITOWG>2.0.ZU;2-1
Fonte:
ISI
Lingua:
ENG
Soggetto:
PROLONGED INFUSION; PANCREATIC-CANCER; BREAST-CANCER;
Keywords:
gemcitabine; phase I; prolonged infusion; refractory;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
8
Recensione:
Indirizzi per estratti:
Indirizzo: Maurel, J Clin Univ Hosp, Hematooncol Dept ICMHO, Med Oncol Serv, c Villarroel 170, Barcelona 08036, Spain Clin Univ Hosp c Villarroel 170 BarcelonaSpain 08036 36, Spain
Citazione:
J. Maurel et al., "Phase I trial of weekly gemcitabine at 3-h infusion in refractory, heavilypretreated advanced solid tumors", ANTI-CANC D, 12(9), 2001, pp. 713-717

Abstract

Gemcitabine (2',2'-difluorodeoxycytidine) is a nucleoside analog with antitumor activity against a variety of malignancies. The critical enzyme cytidine kinase is saturated at plasma concentrations achieved after a 30-min infusion at conventional doses. Prolonged infusion time may yield higher intracellular dFdCTP concentrations. A phase I study was designed to determine the maximum tolerated dose (MTD) of gemcitabine, given by infusion for 3 h,in heavily pretreated patients. Twenty-seven patients (13 head and neck cancer, seven sarcoma, three esophageal cancer, three non-small-cell lung cancer and one ovarian cancer) were enrolled. Twenty patients were defined as refractory at first- or second-line chemotherapy. Four different entry doselevels (300, 400, 450 and 500 mg/m(2)) were evaluated for gemcitabine administered on days 1, 8 and 15 of a 28-day cycle. The MTD was defined as 450 mg/m(2), with granulocytopenia, thrombocytopenia and asthenia being dose limiting. The maximum grade III/IV patient toxicities for hemoglobin, leukocytes, neutrophils and platelets for all doses were 7, 19, 19 and 11%, respectively. Nonhematological toxicities included asthenia, nausea/vomiting and diarrhea. Thus, gemcitabine administered at a fixed 3-h infusion was well tolerated up to 450 mg/m(2) in heavily pretreated patients. Myelosupression and asthenia were dose-limiting toxicities. [(C) 2001 Lippincott Williams &Wilkins.].

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 28/09/20 alle ore 23:46:06